Business

Biotech By Adam Feuerstein and Matthew Herper

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

Biotech By Adam Feuerstein

Drug makers grounding salespeople as coronavirus impact on business spreads

Biotech By Damian Garde and Adam Feuerstein

How one company made $208 million on an untested coronavirus vaccine

Business By Scott Kirsner — Boston Globe

The Engine at MIT is revving up the potential of ‘tough tech’

Biotech By Jonathan Saltzman — Boston Globe

Thermo Fisher buys Dutch diagnostics company for $11.5 billion

Biotech By Matthew Herper

CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven

Biotech By Adam Feuerstein

Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease

Biotech By Adam Feuerstein

With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption

Biotech By Jonathan Saltzman — Boston Globe

Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison

Biotech By Adam Feuerstein

Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk

Opinions Plus By Jonathan P. Gertler

Why medtech is a different beast than biotech in the life sciences pack

Biotech By Adam Feuerstein

With new combination drug data, Exelixis takes another shot at prostate cancer treatment

Adam's Take By Adam Feuerstein

Investor impatience with Gilead reclamation project sparks acquisition chatter

Biotech By Jonathan Saltzman — Boston Globe

Beam Therapeutics raises $180 million in IPO

Health Tech By Erin Brodwin

Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so

Biotech By Adam Feuerstein

Biogen wins patent challenge to key multiple sclerosis drug

Business By Matthew Herper

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

Exclusive By Erin Brodwin

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

Biotech By Adam Feuerstein

FDA approves the first treatment for peanut allergy, but commercial success is hardly assured

Biotech By Adam Feuerstein

European regulators could take a harder line on the review of an Agios blood cancer drug

Adam's Take By Adam Feuerstein

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

Biotech By Jonathan Saltzman — Boston Globe

Spring Bank scraps hepatitis R&D after patient dies in trial

Business By Adam Feuerstein

Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter

Biotech By Sharon Begley

Three star scientists announce plan to solve biotech’s ‘missing women’ problem

Business By Andrew Joseph

Prosecutors identified ‘Pharma Co. X’ as central to alleged opioid kickback scheme. Was it Purdue?

Biotech By Adam Feuerstein

Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks

Biotech By Adam Feuerstein

Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial

Biotech By Scott Kirsner — Boston Globe

The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: serendipity

Pharma By Jonathan Saltzman — Boston Globe

Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme